LOS ANGELES - Abraxis BioScience Inc. said Friday a subsidiary bought more than 15 million common shares of ProMetic Life Sciences Inc., giving it a 4 percent stake in the Canadian biotech company.
Abraxis acquired the shares for 47 Canadian cents (44 cents) each. Abraxis may acquire up to nearly 56 million additional shares for the same per-share price upon the meeting of certain goals during the next 42 months, giving it 19 percent of the outstanding common shares of ProMetic.
Thursday the companies said they agreed to develop and market four biotech drugs.
Desperate U.S. automakers ran into fresh obstacles from skeptical lawmakers Thur...
Shares of Eastman Chemical Co. dropped Tuesday after the chemicals maker said it expect its fourth-quarter earnings to widely miss guidance due t...
Nomura Holdings Inc.<8604.T> announced Thursday that it will cut up to 1,000 European employees for costs reduction. Japan’s largest securi...


Get your next web design project done with our los angeles web design team - Best web design with great price.
Baldwin Linguas:
Translations Interpreting Localization:
English French Portuguese Spanish
Building your business and corporate credit for your small business.